GlucoTrack Management
Management criteria checks 3/4
GlucoTrack's CEO is Paul Goode, appointed in Nov 2021, has a tenure of 3.5 years. total yearly compensation is $350.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.074% of the company’s shares, worth $2.94K. The average tenure of the management team and the board of directors is 1.8 years and 4.8 years respectively.
Key information
Paul Goode
Chief executive officer
US$350.0k
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 3.5yrs |
| CEO ownership | 0.07% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$350k | US$350k | -US$23m |
| Sep 30 2024 | n/a | n/a | -US$15m |
| Jun 30 2024 | n/a | n/a | -US$12m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$483k | US$225k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$5m |
| Dec 31 2022 | US$540k | US$201k | -US$4m |
| Sep 30 2022 | n/a | n/a | -US$5m |
| Jun 30 2022 | n/a | n/a | -US$5m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$29k | n/a | -US$4m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$3m |
| Dec 31 2020 | US$1k | n/a | -US$3m |
Compensation vs Market: Paul's total compensation ($USD350.00K) is below average for companies of similar size in the US market ($USD681.28K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Goode (55 yo)
3.5yrs
Tenure
US$350,000
Compensation
Mr. Paul V. Goode, Ph D., serves as Chief Executive Officer at GlucoTrack, Inc. since November 2021 and President and also serves as its Director since September 2024. He served as President and Chief Oper...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.5yrs | US$350.00k | 0.074% $ 2.9k | |
| Co-Founder | 24.3yrs | US$187.39k | no data | |
| Co-Founder | 24.3yrs | US$199.35k | no data | |
| CFO, Treasurer & Secretary | less than a year | no data | no data | |
| Vice President of Operations | less than a year | no data | 0.00031% $ 12.3 | |
| Chief Scientific Officer | less than a year | US$176.21k | 0% $ 0 | |
| Vice President of Marketing | 1.8yrs | no data | 0% $ 0 |
1.8yrs
Average Tenure
57yo
Average Age
Experienced Management: GCTK's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$350.00k | 0.074% $ 2.9k | |
| Co-Founder | 8.2yrs | US$187.39k | no data | |
| Independent Chairman | 3.9yrs | US$120.00k | 0.55% $ 21.9k | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 15.3yrs | US$100.00k | 0.0021% $ 84.9 | |
| Member of Scientific & Clinical Advisory Board | 10.3yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 5.6yrs | US$100.00k | 0.0017% $ 65.8 | |
| Chair of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Independent Director | 1.8yrs | US$100.00k | 0.17% $ 6.8k | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data |
4.8yrs
Average Tenure
68.5yo
Average Age
Experienced Board: GCTK's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 10:10 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GlucoTrack, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.